The emergence of mouse models of atherosclerosis and their relevance to clinical research

Journal of Internal Medicine

Volumn 242, Issue 2, 1997, Pages 99-109

  Smith, Jonathan D ^a   Breslow, J L ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Atherosclerosis; Mice; Mutant strains; Transgenics

Indexed keywords

APOLIPOPROTEIN E; LOW DENSITY LIPOPROTEIN RECEPTOR;

ATHEROGENESIS; ATHEROSCLEROSIS; DIET; LIPOPROTEIN METABOLISM; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEFICIENCY; REVIEW; TRANSGENIC MOUSE;

EID: 0030842523     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1997.00197.x     Document Type: Review

References (99)

1. Breslow JL. Why you should support the American Heart Association. Circulation 1996; 94: 3016-22.
2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.
3. Khan BV, Parthasarathy SS, Alexander RW, Medford RM. Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J Clin Invest 1995; 95: 1262-70.
4. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 1996; 94: 2013-20.
5. Crouse JR. Progress in coronary artery disease risk-factor research. What remains to be done? Clin Chem 1984; 30: 1125-7.
6. Buja LM, Kita T, Goldstein JL, Watanabe Y, Brown MS. Cellular pathology of progressive atherosclerosis in the WHHL rabbit. An animal model of familial hypercholesterolemia. Arteriosclerosis 1983; 3: 87-101.
7. Breslow JL. Insights into lipoprotein metabolism from studies in transgenic mice. Annu Rev Physiol 1994; 56: 797-810.
8. Vesselinovitch D, Wissler RW. Experimental production of atherosclerosis in mice: II. Effects of atherogenic and high-fat diets on vascular changes in chronically and acutely irradiated mice. J Atheroscler Res 1968; 8: 497-523.
9. Vesselinovitch D, Wissler RW, Doull J. Experimental production of atherosclerosis in mice: I. Effect of various synthetic diets and radiation on survival time, food consumption and body weight in mice. J Atheroscler Res 1968; 8: 483-95.
10. Thompson JS. Atheromata in an inbred strain of mice. J Atheroscler Res 1969; 10: 113-22.
11. Thomas WA, Hartroft WS. Myocardial infarction in rats fed diets containing high fat. cholesterol, thiouracil, and sodium cholate. Circulation 1959; 19: 65.
12. Roberts A, Thompson JS. Inbred mice and their hybrids as an animal model for atherosclerosis research. Adv Exp Med Biol 1976; 67: 313-27.
13. Breckenridge WC, Roberts A, Kuksis A. Lipoprotein levels in genetically selected mice with increased susceptibility to atherosclerosis. Arteriosclerosis 1985; 5: 256-64.
14. Paigen B, Havens MB, Morrow A. Effect of 3-methylcholanthrene on the development of aortic lesions in mice. Cancer Res 1985; 45: 3850-55.
15. Paigen B, Morrow A, Brandon C, Mitchell D, Holmes P. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis 1985; 57: 65-73.
16. Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 1987; 68: 231-40.
17. Stewart-Phillips JL, Lough J. Pathology of atherosclerosis in cholesterol-fed, susceptible mice. Atherosclerosis 1991; 90: 211-18.
18. Mehrabian M, Demer LL, Lusis AJ. Differential accumulation of intimal monocyte-macrophages relative to lipoproteins and lipofuscin corresponds to hemodynamic forces on cardiac valves in mice. Arterioscler Thromb 1991; 11: 947-57.
19. Qiao JH, Xie PZ, Fishbein MC, Kreuzer J, Drake TA, Demer LL, Lusis AJ. Pathology of atheromatous lesions in inbred and genetically engineered mice. Genetic determination of arterial calcification. Arterioscler Thromb 1994; 14: 1480-97.
20. Paigen B, Mitchell D, Reue K, Morrow A, Lusis AJ, LeBoeuf RC. Ath-1, a gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice. Proc Natl Acad Sci USA 1987; 84: 3763-7.
21. Mehrabian M, Qiao JH, Hyman R, Ruddle D, Laughton C, Lusis AJ. Influence of the apoA-II gene locus on HDL levels and fatty streak development in mice. Arterioscler Thromb 1993; 13: 1-10.
22. Paigen B, Albee D, Holmes PA, Mitchell D. Genetic analysis of murine strains C57BL/6J and C3H/HeJ to confirm the map position of Ath-1, a gene determining atherosclerosis susceptibility. Biochem Genetics 1987; 25: 501-11.
23. Paigen B, Mitchell D, Holmes PA, Albee D. Genetic analysis of strains C57BL/6J and BALB/cJ for Ath-1, a gene determining atherosclerosis susceptibility in mice. Biochem Genetics 1987; 25: 881-92.
24. LeBoeuf RC, Doolittle MH, Montcalm A, Martin DC, Reue K, Lusis AJ. Phenotypic characterization of the Ath-1 gene controlling high density lipoprotein levels and susceptibility to atherosclerosis. J Lipid Res 1990; 31: 91-101.
25. Paigen B, Nesbitt MN, Mitchell D, Albee D, LeBoeuf RC. Ath-2, a second gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice. Genetics 1989; 122: 163-8.
26. Stewart-Phillips JL, Lough J, Skamene E. ATH-3, a new gene for atherosclerosis in the mouse. Clin Invest Med 1989; 12: 121-6.
27. Hyman RW, Frank S, Warden CH, Daluiski A, Heller R, Lusis AJ. Quantitative trait locus analysis of susceptibility to diet-induced atherosclerosis in recombinant inbred mice. Biochem Genetics 1994; 32: 397-107.
28. Warden CH, Fisler JS, Pace MJ, Svenson KL, Lusis AJ. Coincidence of genetic loci for plasma cholesterol levels and obesity in a multifactorial mouse model. J Clin Invest 1993; 92: 773-9.
29. Qiao JH, Welch CL, Xie PZ, Fishbein MC, Lusis AJ. Involvement of the tyrosinase gene in the deposition of cardiac lipofuscin in mice. Association with aortic fatty streak development. J Clin Invest 1993; 92: 2386-93.
30. Renier G, Skamene E, DeSanctis JB, Radzioch D. High macrophage lipoprotein lipase expression and secretion are associated in inbred murine strains with susceptibility to atherosclerosis. Arterioscler Thromb 1993; 13: 190-96.
31. Liao F, Andalibi A, deBeer FC, Fogelman AM, Lusis AJ. Genetic control of inflammatory gene induction and NF-κ B-like transcription factor activation in response to an atherogenic diet in mice. J Clin Invest 1993; 91: 2572-9.
32. Liao F, Andalibi A, Qiao JH, Allayee H, Fogelman AM, Lusis AJ. Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice. J Clin Invest 1994; 94: 877-84.
33. Fyfe AI, Qiao JH, Lusis AJ. Immune-deficient mice develop typical atherosclerotic fatty streaks when fed an atherogenic diet. J Clin Invest 1994; 94: 2516-20.
34. Emeson EE, Shen ML, Bell CG, Qureshi A. Inhibition of atherosclerosis in CD4 T-cell-ablated and nude (nu/nu) C57BL/6 hyperlipidemic mice. Am J Pathol 1996; 149: 675-85.
35. Emeson EE, Manaves V, Singer T, Tabesh M. Chronic alcohol feeding inhibits atherogenesis in C57BL/6 hyperlipidemic mice. Am J Pathol 1995; 147: 1749-58.
36. Nagata Y, Yonemoto M, Iwasawa Y, Shimizu-Nagumo A, Hattori H, Sawazaki Y, Kamei T. N-[2-[N'-pentyl-(6, 6-dimethyl - 2.4 - heptadiynyl)amino]ethyl] - (2-methyl - 1 - nap - thylthio) acetamide (FY- 087). A new acyl coenzyme a: cholesterol acyltransferase (ACAT) inhibitor of diet-induced atherosclerosis formation in mice. Biochem Pharmacol 1995; 49: 643-51.
37. Kunjathoor VV, Wilson DL, LeBoeuf RC. Increased atherosclerosis in streptozotocin-induced diabetic mice. J Clin Invest 1996; 97: 1767-73.
38. Lin AH, Castle CK, Melchior GW, Marotti KR. The effect of population density on the development of experimental atherosclerosis in female mice. Atherosclerosis 1995; 115: 85-8.
39. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992; 71: 343-53.
40. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258: 468-71.
41. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994; 14: 133-40.
42. Plump AS, Breslow JL. Apolipoprotein E and the apolipoprotein E-deficient mouse. Annu Rev Nutr 1995; 15: 495-518.
43. Reddick RL, Zhang SH, Maeda N. Atherosclerosis in mice lacking apoE. Evaluation of lesional development and progression. Arterioscler Thromb 1994; 14: 141-7.
44. Roselaar SE, Kakkanathu PX, Daugherty A. Lymphocyte populations in atherosclerotic lesions of apoE -/-and LDL receptor -/- mice. Decreasing density with disease progression. Arterioscler Thromb Vasc Biol 1996; 16: 1013-18.
45. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA 1995; 92: 8264-8.
46. Zhou X, Stemme S, Hansson GK. Evidence for a local immune response in atherosclerosis. CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice. Am J Pathol 1996; 149: 359-66.
47. Palinski W, Ord VA, Plump AS, Breslow JL, Steinberg D, Witztum JL. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb 1994; 14: 605-16.
48. Tangirala RK, Rubin EM, Palinski W. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J Lipid Res 1995; 16: 2320-28.
49. Syme SL, Marmot MG, Kagan A, Kato H, Rhoads G. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan. Hawaii and California: introduction. Am J Epidemiol 1975; 102: 477-80.
50. Stoudemire JB, Garnick MB. Effects of recombinant human macrophage colony-stimulating factor on plasma cholesterol levels. Blood 1991; 77: 750-55.
51. Motoyoshi K, Takaku E. Serum cholesterol-lowering activity of human monocytic colony-stimulating factor. Lancet 1989; 2: 326-7.
52. Schaub RG, Bree MP, Hayes LL, Rudd MA, Rabbani L, Loscalzo J, Clinton SK. Recombinant human macrophage colony-stimulating factor reduces plasma cholesterol and carrageenan granuloma foam cell formation in Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb 1994; 14: 70-76.
53. Dansky HM, Charlton SA, McGee Harper M, Smith JD. T and B lymphocytes play a minor role in atheroscleritic plaque formation in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA 1997; 94: 4642-6.
54. Paszty C, Maeda N, Verstuyft J, Rubin KM. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 1994; 94: 899-903.
55. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-1 gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A 1994; 91: 9607-11.
56. Moghadasian MH, McManus BM, Pritchard PH, Frohlich IJ. 'Tall Oil'-derived pytosterols reduce atherosclerosis in apoE-deficient mice. Arterioscler Thromb Vasc Biol 1997; 17: 119-26.
57. Bourassa PA, Milos PM, Gaynor BJ, Breslow JL, Aiello RJ. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 1996; 93: 10022-7.
58. Tangirala RK, Casanada F, Miller E, Witztum JL, Steinberg D, Palinski W. Effect of the antioxidant N,N'-diphenyl, 1,4-phenylenediamine (DPPD) on atherosclerosis in apoE-deficient mice. Arterioscler Thromb Vasc Biol 1995; 15: 1625-30.
59. Stevenson SC, Marshall-Neff J, Teng B, Lee CB, Roy S, McClelland A. Phenotypic correction of hypercholesterolemia in apoE-deficient mice by adenovirus-mediated in vivo gene transfer. Arterioscler Thromb Vasc Biol 1995; 15: 479-84.
60. Kashyap VS, Santamarina-Fojo S, Brown DR, Parrott CL. Applebaum-Bowden D, Meyn S et al. Apolipoprotein E deficiency in mice: gene replacement and prevention of atherosclerosis using adenovirus vectors. J Clin Invest 1995; 96: 1612-20.
61. Smith JD, Wong E, Ginsberg M. Cytochrome P450 1A. 1. promoter as a genetic switch for the regulatable and physiological expression of a plasma protein in transgenic mice. Proc Natl Acad Sci USA 1930; 1995: 92: 11926-30.
62. Kraft HG, Menzel HJ, Hoppichler F, Vogel W, Utermann G. Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. J Clin Invest 1989; 83: 137-42.
63. Linton MF, Gish R, Hubl ST, Butler E, Esquivel C, Bry WI, et al. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J Clin Invest 1991; 88: 270-81.
64. Mahley RW. Apolipoprotein E. cholesterol transport protein with expanding role in cell biology. Science 1988; 240: 622-30.
65. Linton MF, Atkinson JB, Fazio S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science 1995; 267: 1034-7.
66. Boisvert WA, Spangenberg J, Curtiss LK. Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by bone marrow transplantation. J Clin Invest 1995; 96: 1118-24.
67. Basu SK, Brown MS, Ho YK, Havel RJ, Goldstein JL. Mouse macrophages synthesize and secrete a protein resembling apolipoprotein E. Proc Natl Acad Sci U S A 1981; 78: 7545-9.
68. Getz GS, Mazzone T, Soltys P, Bates SR. Atherosclerosis and apoprotein E. An enigmatic relationship. Arch Pathol Lab Med 1988; 112: 1048-55.
69. Smith JD, Miyata M, Ginsberg M, Grigaux C, Shmookler E, Plump AS. Cyclic AMP induces apolipoprotein E binding activity and promotes cholesterol efflux from a macrophage cell line to apolipoprotein acceptors. J Biol Chem 1996; 271: 30647-55.
70. Oram JF, Yokoyama S. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J Lipid Res 1996; 37: 2473-91.
71. Bellosta S, Mahley RW, Sanan DA, Murata J, Newland DL, Taylor JM, Pitas RE. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J Clin Invest 1995; 96: 2170-79.
72. Russell PS, Chase CM, Colvin RB. Accelerated atheromatous lesions in mouse hearts transplanted to apolipoprotein-E-deficient recipients. Am J Pathol 1996; 149: 91-9.
73. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993; 92: 883-93.
74. Ishibashi S, Goldstein JL, Brown MS, Herz J, Burns DK. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest 1994; 93: 1885-93.
75. Masucci-Magoulas L, Goldberg IJ, Bisgaier CL, Serajuddin H, Francone OL, Breslow JL, Tall AR. A mouse model with features of familial combined hyperlipidemia. Science 1997; 275: 391-1.
76. Mulder M, Lombardi P, Jansen H, van Berkel TJ, Frants RR, Havekes LM. Low density lipoprotein receptor internalizes low density and very low density lipoproteins that are bound to heparan sulfate proteoglycans via lipoprotein lipase. J Biol Chem 1993; 268: 9369-75.
77. Shimada M, Ishibashi S, Inaba T, Yagyu H, Harada K, Osuga JI et al. Suppression of diet-induced atherosclerosis in low density lipoprotein receptor knockout mice overexpressing lipoprotein lipase. Pror Natl Acad Sci U S A 1996; 93: 7242-6.
78. Rubin EM, Smith DJ. Atherosclerosis in mice: getting to the heart of a polygenic disorder. Trends Genet 1994; 10: 199-203.
79. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 1991; 353: 265-7.
80. Warden CH, Hedrick CC, Qiao JH, Castellani LW, Lusis AJ. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science 1993; 261: 469-72.
81. Schultz JR, Rubin EM. The properties of HDL in genetically engineered mice. Curr Opin Lipidol 1994; 5: 126-37.
82. Schultz JR, Verstuyft JG, Gong EL, Nichols AV, Rubin EM. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature 1993; 365: 762-4.
83. Duverger N, Tremp G, Caillaud JM, Emmanuel F, Castro G, Fruchart JC et al. Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science 1996; 273: 966-8.
84. Mancini FP, Newland DL, Mooser V, Murata J, Marcovina S, Young SG et al. Relative contributions of apolipoprotein(a) and apolipoprotein-B to the development of fatty lesions in the proximal aorta of mice. Arterioscler Thromb Vasc Biol 1995; 15: 1911-16.
85. Lawn RM, Wade DP, Hammer RE, Chiesa G, Verstuyft JG, Rubin EM. Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature 1992; 360: 670-72.
86. Liu AC, Lawn RM, Verstuyft JG, Rubin EM. Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein(a) in transgenic mice. J Lipid Res 1994; 35: 2263-7.
87. Purcell-Huynh DA, Farese RV Jr, Johnson DF, Flynn LM, Pierotti V, Newland DL et al. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J Clin Invest 1995; 95: 2246-57.
88. Mortimer BC, Redgrave TG, Spangler EA, Verstuyft JG, Rubin EM. Effect of human apoE4 on the clearance of chylomicron-like lipid emulsions and atherogenesis in transgenic mice. Arterioscler Thromb 1994; 14: 1542-52.
89. Shimano H, Ohsuga J, Shimada M, Namba Y, Gotoda T, Harada K et al. Inhibition of diet-induced atheroma formation in transgenic mice expressing apolipoprotein E in the arterial wall. J Clin Invest 1995; 95: 469-76.
90. Fazio S, Sanan DA, Lee YL, Ji ZS, Mahley RW, Rall SC Jr. Susceptibility to diet-induced atherosclerosis in transgenic mice expressing a dysfunctional human apolipoprotein E (Arg 112. Cys142). Arterioscler Thromb 1994; 14: 1873-9.
91. van Vlijmen BJ, van den Maagdenberg AM, Gijbels MJ, van der Boom H, HogenEsch H, Frants RR et al. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J Clin Invest 1994; 93: 1403-10.
92. Shimano H, Yamada N, Katsuki M, Shimada M, Gotoda T, Harada K et al. Overexpression of apolipoprotein E in transgenic mice: marked reduction in plasma lipoproteins except high density lipoprotein and resistance against diet-induced hypercholesterolemia. Proc Natl Acad Sci U S A 1992; 89: 1750-54.
93. Marotti KR, Castle CK, Boyle TP, Lin AH, Murray RW, Melchior GW. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 1993; 364: 73-5.
94. Hayek T, Masucci-Magoulas L, Jiang X, Walsh A, Rubin E, Breslow JL, Tall AR. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest 1995; 96: 2071-4.
95. Busch SJ, Barnhart RL, Martin GA, Fitzgerald MC, Yates MT, Mao SJ et al. Human hepatic triglyceride lipase expression reduces high density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice. J Biol Chem 1994; 269: 16376-82.
96. Li H, Reddick RL, Maeda N. Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice. Arterioscler Thromb 1993; 13: 1814-21.
97. Zhang SH, Reddick RL, Burkey B, Maeda N. Diet-induced atherosclerosis in mice heterozygous and homozygous for apolipoprotein E gene disruption. J Clin Invest 1994; 94: 937-45.
98. van Ree JH, van den Broek WJ, Dahlmans VE, Groot PH, Vidgeon-Hart M, Frants RR et al. Diet-induced hypercholesterolemia and atherosclerosis in heterozygous apolipoprotein E-deficient mice. Atherosclerosis 1996; 111: 25-37.
99. Schreyer SA, Peschon JJ, LeBoeuf RC. Accelerated atherosclerosis in mice lacking tumor necrosis factor receptor p55 J Biol Chem 1996; 271: 26174-8.